Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
July 31, 2026 62.36%
April 30, 2026 63.59%
January 31, 2026 63.21%
October 31, 2025 56.42%
July 31, 2025 60.55%
April 30, 2025 62.79%
January 31, 2025 63.29%
October 31, 2024 61.62%
July 31, 2024 61.09%
April 30, 2024 61.63%
January 31, 2024 61.56%
October 31, 2023 60.40%
July 31, 2023 60.56%
April 30, 2023 61.14%
January 31, 2023 59.64%
October 31, 2022 58.74%
July 31, 2022 60.71%
April 30, 2022 58.01%
January 31, 2022 60.48%
October 31, 2021 61.36%
July 31, 2021 62.60%
April 30, 2021 62.54%
January 31, 2021 61.13%
October 31, 2020 57.19%
July 31, 2020 57.11%
Date Value
April 30, 2020 58.26%
January 31, 2020 61.48%
October 31, 2019 61.12%
July 31, 2019 61.29%
April 30, 2019 61.10%
January 31, 2019 61.47%
October 31, 2018 60.91%
July 31, 2018 59.79%
April 30, 2018 59.59%
January 31, 2018 58.58%
October 31, 2017 60.80%
July 31, 2017 61.20%
April 30, 2017 63.52%
January 31, 2017 59.37%
October 31, 2016 54.23%
July 31, 2016 58.48%
April 30, 2016 59.75%
January 31, 2016 56.95%
October 31, 2015 54.17%
July 31, 2015 59.15%
April 30, 2015 59.95%
January 31, 2015 60.98%
October 31, 2014 56.75%
July 31, 2014 63.32%
April 30, 2014 63.31%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Globus Medical, Inc. 65.92%
Stryker Corp. 66.14%
Boston Scientific Corp. 66.50%
West Pharmaceutical Services, Inc. 37.83%
IDEXX Laboratories, Inc. 64.07%